Cargando…
Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling
Artemether-lumefantrine (AL) is the most widely-recommended treatment for uncomplicated Plasmodium falciparum malaria worldwide. Its safety and efficacy have been extensively demonstrated in clinical trials; however, its performance in routine health care settings, where adherence to drug treatment...
Autores principales: | Challenger, Joseph D., Bruxvoort, Katia, Ghani, Azra C., Okell, Lucy C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680187/ https://www.ncbi.nlm.nih.gov/pubmed/29123086 http://dx.doi.org/10.1038/s41467-017-01352-3 |
Ejemplares similares
-
Asymptomatic recrudescence after artemether–lumefantrine treatment for uncomplicated falciparum malaria: a systematic review and meta-analysis
por: Mumtaz, Rida, et al.
Publicado: (2020) -
A comparison of the duration of post-treatment protection of artemether-lumefantrine, dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated malaria
por: Bretscher, Michael T, et al.
Publicado: (2014) -
How delayed and non-adherent treatment contribute to onward transmission of malaria: a modelling study
por: Challenger, Joseph D, et al.
Publicado: (2019) -
Artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria
por: Ehrhardt, Stephan, et al.
Publicado: (2009) -
Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria
por: Tchaparian, Eskouhie, et al.
Publicado: (2016)